Double-stranded RNA (DSRNA) and method of use for inhibiting expression of the AML-1/MTG8 fusion gene
View Patent ↗The present invention relates to the specific inhibition of expression of a fusion gene in mammals using a short double stranded RNA. The dsRNA is approximately 19–24 nucleotides in length, and has a nucleotide sequence which is complementary to at least a part of the target gene. The dsRNAs of the present invention are useful for treating diseases caused by chromosomal aberrations, particularly malignant diseases such as lymphoma and leukemia.
1. An isolated double stranded ribonucleic add molecule (dsRNA) comprising two separate non-linked RNA strands, a strand S1 and a complementary RNA strand, wherein said S1 strand and said complementary strand consists of from 20 to less than 30 nucleotides in length and said S1 strand being complementary to a region of a target fusion gene comprising the fusion site in said target fusion gene, and wherein said target fusion gene is created by the fusion of two genes in a cell as a result of chromosomnal aberration wherein the S1 strand consists of the sequence SEQ ID NO:1 and said complementary RNA strand consists of the sequence SEQ ID NO: 2.
2. A dsRNA according to claim 1 , wherein at least one end of the dsRNA is modified, in order to counteract degradation in the cell or dissociation into the individual strands.